Europe Hepatitis Delta Virus Hdv Infection Market
市场规模（十亿美元）
CAGR :
% 
USD
21.62 Million
USD
33.19 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 21.62 Million |
 Market Size (Forecast Year) |
USD 33.19 Million |
 CAGR |
% |
| Major Markets Players |
|
歐洲丁型肝炎病毒 (HDV)感染市場細分，按類型（急性丁型肝炎和慢性丁型肝炎）、治療（手術（肝臟移植）和藥物治療）、藥物類型（品牌藥和仿製藥）、給藥途徑（口服和腸外給藥）、年齡組（成人、老年人和兒童）、性別（女性和男性）、傳播方式（受污染的針頭、接觸受感染的血液、血液和血漿製品輸血等）、最終用戶（醫院、專科診所、家庭護理機構、研究機構和學術中心、門診手術中心等）、分銷渠道（直接投標、零售等） - 產業趨勢和預測至 2032 年
歐洲丁型肝炎病毒（HDV）感染市場規模
- 2024 年歐洲丁型肝炎病毒 (HDV) 感染市場規模價值2,162 萬美元 ，預計 到 2032 年將達到 3,319 萬美元，預測期內 複合年增長率為 5.50%
- 市場成長主要得益於歐洲各地意識的提高、診斷技術的改進和監測系統的增強，從而可以更早發現並更有效地管理 HDV 感染
- 此外，抗病毒研究投入的不斷增加、政府消除肝炎的措施以及新型療法的引入，正在顯著改善治療的可及性和患者療效。這些因素共同推動了對丁型肝炎（HDV）感染解決方案的需求，從而極大地促進了市場擴張。
歐洲丁型肝炎病毒（HDV）感染市場分析
- 丁型肝炎病毒 (HDV) 感染是乙型肝炎的一種嚴重合併感染，由於其會迅速發展為肝硬化和肝細胞癌，因此引起了嚴重的公共衛生問題，從而推動了整個歐洲對早期檢測、有效治療和公共衛生幹預策略的需求不斷增加
- 市場成長主要得益於人們意識的提高、診斷能力的提高以及擁有強大醫療保健體系的歐洲主要國家針對 HDV 的研究計劃的增加。
- 德國在歐洲丁型肝炎病毒 (HDV) 感染市場佔據主導地位，2024 年的收入份額最高，為 29.9%，這得益於其全面的肝炎篩檢計劃、政府支持的疾病消除計劃以及專注於肝病的主要製藥公司的存在
- 義大利預計將成為預測期內歐洲丁型肝炎病毒 (HDV) 感染市場成長最快的國家，因為義大利的 HDV 盛行率歷來較高，患者外展計畫得到改善，並且在管理慢性肝病方面醫療保健投資不斷增加
- 慢性丁型肝炎佔據歐洲丁型肝炎病毒 (HDV) 感染市場的主導地位，2024 年的市場份額為 73%，這是由於其長期疾病負擔需要持續治療、監測和更高的醫療資源利用率
報告範圍和歐洲丁型肝炎病毒 (HDV) 感染市場細分
|
屬性 |
歐洲丁型肝炎病毒 (HDV) 感染關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
歐洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
歐洲丁型肝炎病毒（HDV）感染市場趨勢
“轉向標靶治療和精準診斷”
- 歐洲 HDV 感染市場的一個主要發展趨勢是從傳統的干擾素治療到標靶抗病毒治療和精準診斷方法的轉變，旨在更好地管理疾病並改善患者預後
- 例如，歐洲藥品管理局 (EMA) 有條件批准了首創丁型肝炎病毒 (HDV) 進入抑制劑 Hepcludex（布列韋肽），標誌著慢性丁型肝炎患者治療領域的重大突破。該藥物在臨床上的日益普及正在重塑歐洲各地的治療方案。
- 此外，採用先進的分子診斷工具，包括 HDV RNA 定量分析和基因分型，可實現更早、更準確的診斷，對於及時介入和改善預後至關重要
- 德國、義大利和法國等國的國家衛生系統正越來越多地將丁型肝炎篩檢納入更廣泛的乙肝計畫中，特別是針對移民、靜脈注射毒品使用者和同時感染愛滋病毒的個人等高風險族群
- 個人化醫療的趨勢得到了不斷增加的研究資金、現實世界證據收集以及學術機構和製藥公司之間的戰略夥伴關係的支持
- 隨著醫療保健系統優先考慮消除病毒性肝炎的目標，對新型治療方案和敏感診斷的需求預計將激增，為持續創新和市場擴張奠定基礎
歐洲丁型肝炎病毒（HDV）感染市場動態
司機
“病毒性肝炎盛行率上升及國家消除策略”
- 丁型肝炎合併感染的負擔日益加重，尤其是在慢性B型肝炎患者中，加上公共衛生部門對肝炎消除計畫的日益關注，是加速整個歐洲市場成長的關鍵驅動力
- 例如，德國的國家肝炎策略包括對乙肝病毒和丁肝病毒進行全面篩檢，同時為獲得創新抗病毒療法提供補貼，以推動早期診斷和提高治療率
- 世界衛生組織的目標是到 2030 年消除病毒性肝炎，這促使一些歐洲國家加強監測、宣傳和護理聯繫工作，為製藥和診斷公司創造了更多機會
- 此外，布韋肽等報銷療法的普及以及正在進行的聯合療法臨床試驗正在鼓勵更多患者尋求治療
- 醫療保健系統、研究機構和政策制定者之間的協調回應正在顯著擴大 HDV 治療和診斷領域
克制/挑戰
“主要市場疾病認知度低且診斷受限”
- 阻礙歐洲丁型肝炎感染市場發展的一大挑戰是醫療保健提供者和高風險族群對疾病的認識不足，導致診斷不足和治療延遲
- 許多慢性B肝患者仍然不知道可能同時感染了丁肝病毒，因為丁肝病毒檢測並未在所有國家的標準乙肝病毒管理中一致納入
- 例如，東歐和南歐部分地區在篩檢覆蓋率和診斷基礎設施方面仍然存在差距，尤其是在農村地區和移民社區
- 此外，在資源匱乏的地區，專門的 HDV RNA 檢測成本高且可用性有限，使得準確追蹤盛行率和擴大治療計劃變得困難
- 克服這些障礙需要齊心協力改善臨床教育，擴大國家篩檢方案，並確保不同醫療環境中的診斷和治療選擇公平可及
歐洲丁型肝炎病毒（HDV）感染市場範圍
市場根據類型、治療、藥物類型、給藥途徑、年齡層、性別、傳播、最終用戶和分銷管道進行細分。
- 按類型
根據感染類型，歐洲丁型肝炎病毒 (HDV) 感染市場分為急性丁型肝炎和慢性丁型肝炎。慢性丁型肝炎佔據市場主導地位，2024 年其市場收入份額最高，達到 73%，這得益於其長期性，需要持續的臨床護理和藥物幹預。慢性丁型肝炎會增加肝硬化和肝細胞癌的風險，因此需要更積極、更持久的治療策略。
由於診斷技術的進步使得人們能夠在慢性進展發生之前更早地發現和乾預，因此急性丁型肝炎部分預計將在預測期內以最快的複合年增長率增長。
- 按治療
根據治療方法，歐洲丁型肝炎病毒 (HDV) 感染市場細分為手術（肝臟移植）和藥物治療。 2024 年，藥物治療佔 85.7% 的市場份額，佔據主導地位，這得益於聚乙二醇幹擾素等抗病毒藥物的使用增加，以及布洛韋肽等新型標靶療法的採用。這些非侵入性治療方法為疾病的長期管理提供了有效的方法。
預計外科手術（肝臟移植）部分將在預測期內出現最快的增長，因為它服務於一小部分患有終末期肝衰竭的人群，雖然至關重要，但受到捐贈者可用性和程序複雜性的限制。
- 依藥物類型
根據藥物類型，歐洲丁型肝炎病毒 (HDV) 感染市場分為品牌藥和仿製藥。由於專利保護下的新型療法佔據主導地位，且仿製藥競爭有限，品牌藥在 2024 年佔據了 66.2% 的最大市場份額。這些品牌藥有可靠的臨床數據支持，通常受到國家醫療保健系統的青睞。
隨著幹擾素療法專利的到期以及整個歐洲努力降低治療成本，仿製藥領域預計將在 2025 年至 2032 年間見證最快的複合年增長率。
- 依給藥途徑
根據給藥途徑，歐洲丁型肝炎病毒 (HDV) 感染市場分為口服和腸外給藥。腸外給藥在 2024 年佔據最高市場份額，為 69.4%，主要由於聚乙二醇幹擾素和布洛韋肽透過皮下注射給藥。腸外給藥因其在治療慢性丁型肝炎的有效性而受到青睞。
隨著持續的研究開發口服抗病毒藥物，提高患者的依從性和便利性，口服藥物領域預計將在 2025 年至 2032 年間見證最快的複合年增長率。
- 按年齡組
根據年齡組，歐洲丁型肝炎病毒 (HDV) 感染市場可分為成人、老年人和兒童。 2024 年，成人市場佔據主導地位，市佔率達 61.8%，這是因為由於長期合併感染B型肝炎病毒 (HBV)，中年族群中丁型肝炎病毒 (HDV) 感染更為普遍。成人也是丁型肝炎篩檢和治療服務的主要接受者。
隨著篩檢和早期幹預策略的擴大，老年病和兒科疾病領域預計將在預測期內以最快的複合年增長率增長。
- 按性別
歐洲丁型肝炎病毒 (HDV) 感染市場按性別細分為女性和男性。 2024 年，男性市場佔有率更高，達到 54.6%，這得益於流行病學趨勢顯示，由於靜脈注射毒品和職業暴露等風險因素，男性丁型肝炎病毒 (HDV) 感染率更高。
受醫療體系意識增強和醫療服務可近性改善的推動，預測期內女性市場預計將以最快的複合年增長率成長。
- 透過傳輸
根據傳播途徑，歐洲丁型肝炎病毒 (HDV) 感染市場細分為使用受污染針頭、接觸受感染血液、輸血和血漿製品以及其他途徑。 2024 年，接觸受感染血液的市場份額最高，達到 38.1%，這反映了包括醫療操作、損傷和不當消毒等在內的多種風險情況。
預計受污染針頭在預測期內將出現最快的增長，因為它仍然是主要的傳播源，特別是在吸毒人群中，而隨著篩檢方案的改進，血液和血漿製品輸血病例有所減少。
- 按最終用戶
根據最終用戶，歐洲丁型肝炎病毒 (HDV) 感染市場細分為醫院、專科診所、家庭護理機構、研究機構和學術中心、門診手術中心等。醫院佔據主導地位，2024 年的市場份額最高，達到 46.9%，因為這些機構負責大部分診斷檢測、藥物管理和肝臟移植。
由於專科診所專注於傳染病和肝病護理，提供專業服務和後續計劃，預計 2025 年至 2032 年間專科診所的複合年增長率將最快。
- 按分銷管道
根據分銷管道，歐洲丁型肝炎病毒 (HDV) 感染市場細分為直接招標、零售和其他通路。由於歐洲各地公立醫院和衛生當局在集中採購模式下進行批量採購，直接招標成為主導管道，2024 年市場份額達到 53.3%。
預計零售銷售領域將在 2025 年至 2032 年間見證最快的複合年增長率，這得益於藥局和私人醫療機構中品牌藥和仿製藥的日益普及。
歐洲丁型肝炎病毒（HDV）感染市場區域分析
- 德國在歐洲丁型肝炎病毒 (HDV) 感染市場佔據主導地位，2024 年的收入份額最高，為 29.9%，這得益於其全面的肝炎篩檢計劃、政府支持的疾病消除計劃以及專注於肝病的主要製藥公司的存在
- 該國對合併感染管理採取了積極主動的方法，包括對乙肝患者進行常規丁型肝炎病毒檢測以及早期獲得布洛韋肽等創新治療方法，這顯著提高了診斷和護理結果
- 大型製藥和生物技術公司參與肝病研究，加上高額公共衛生投資和臨床醫生意識，進一步鞏固了德國的領導地位，使德國成為歐洲 HDV 感染市場的關鍵成長中心
德國丁型肝炎病毒（HDV）感染市場洞察
2024年，德國丁型肝炎病毒 (HDV) 感染市場佔據歐洲最大收入份額，這得益於其強大的公共衛生體系、早期創新療法的可及性以及旨在消除病毒性肝炎的國家級戰略。德國重視預防性篩檢、全面的B肝護理整合以及藥物創新，為丁型肝炎的診斷和治療創造了良好的環境。持續支持真實世界證據研究和學術合作，使德國成為丁型肝炎管理領域的區域領導者。
義大利丁型肝炎病毒（HDV）感染市場洞察
由於義大利丁型肝炎病毒 (HDV) 的盛行率處於歷史高位，且政府主導了針對合併感染人群的宣傳活動，預計預測期內義大利丁型肝炎病毒 (HDV) 感染市場將實現顯著的複合年增長率。義大利的肝炎消除路線圖強調擴大檢測範圍、推廣公共衛生服務以及透過國家衛生系統提供抗病毒療法。此外，對移民和注射毒品者 (PWID) 等弱勢群體的更多關注預計將進一步推動篩檢和治療需求。
法國丁型肝炎病毒（HDV）感染市場洞察
預計法國丁型肝炎病毒 (HDV) 感染市場將穩步擴張，這得益於其積極主動的肝炎監測、將丁型肝炎病毒檢測納入乙型肝炎護理以及持續開展的臨床研究項目。獲得歐洲藥品管理局 (EMA) 批准的療法和政府報銷機制有助於提高治療的可及性。法國完善的肝病中心以及對歐洲範圍內肝炎策略的參與，有助於形成統一的丁型肝炎預防和管理方法。
西班牙丁型肝炎病毒（HDV）感染市場洞察
在預測期內，西班牙丁型肝炎病毒 (HDV) 感染市場預計將持續成長，這得益於國家策略，這些策略著重於消除肝炎、改進檢測方案以及在高風險社區的推廣。旨在擴大診斷和治療可近性的公私合作夥伴關係和區域衛生倡議正在推動成長。西班牙重視分散式照護和社區幹預，這對於惠及服務匱乏的人至關重要。
英國丁型肝炎病毒（HDV）感染市場洞察
英國丁型肝炎病毒 (HDV) 感染市場預計將在預測期內保持穩定的複合年增長率，這得益於英國致力於消除病毒性肝炎的承諾以及其強大的公共醫療基礎設施。國家衛生指引建議所有B肝病毒陽性患者進行丁型肝炎病毒檢測，以促進早期診斷和就醫。英國參與歐洲丁型肝炎病毒監測計畫、獲得歐洲藥品管理局 (EMA) 批准的治療藥物（例如布列衛肽）以及正在進行的臨床研究，這些都有助於擴大治療前景。此外，針對高風險族群（例如注射毒品者和來自流行地區的移民）的定向篩檢正在增強患者識別和就醫機會。
歐洲丁型肝炎病毒（HDV）感染市場份額
歐洲丁型肝炎病毒 (HDV) 感染產業主要由知名公司主導，包括：
- 吉利德科學公司（美國）
- F. Hoffmann-La Roche Ltd（瑞士）
- 葛蘭素史克公司（英國）
- 百時美施貴寶公司（美國）
- 諾華公司（瑞士）
- 默克公司（美國）
- 艾伯維公司（美國）
- 強生服務公司（美國）
- 賽諾菲公司（法國）
- Zydus Lifesciences Limited（印度）
- 雷迪博士實驗室有限公司（印度）
- Alnylam Pharmaceuticals, Inc.（美國）
- Eiger BioPharmaceuticals, Inc.（美國）
- 拜耳公司（德國）
- Biotest AG（德國）
- Grifols, SA（西班牙）
- Sigma-Tau Industrie Farmaceutiche Riunite SpA（義大利）
- Abivax SA（法國）
歐洲丁型肝炎病毒 (HDV) 感染市場的最新發展如何？
- 2023年9月，吉利德科學公司開發的Hepcludex（布列韋肽）獲得歐洲藥品管理局（EMA）的全面批准，成為治療慢性丁型肝炎（HDV）感染的首創進入抑制劑。這一進展標誌著歐洲HDV治療領域的關鍵時刻，因為該療法在病毒抑制和肝臟酵素恢復正常化方面表現出顯著改善。此次全面批准鞏固了其作為核心治療方案的地位，並反映出監管和臨床對HDV標靶治療的支持日益增強。
- 2023年6月，歐洲肝病研究協會 (EASL) 更新了其臨床實踐指南，納入了針對所有乙肝表面抗原 (HBsAg) 陽性患者的更廣泛的丁型肝炎 (HDV) 篩檢建議。這項臨床政策的轉變凸顯了整個歐洲大陸對早期檢測的推動，這與世界衛生組織 (WHO) 消除病毒性肝炎的目標一致，並推動了對先進診斷和抗病毒療法的需求。
- 2023年5月，義大利衛生部啟動了一項全國性的肝炎宣傳和篩檢活動，強調對移民、注射毒品者（PWID）和被監禁人員等高危險群進行丁型肝炎病毒（HDV）檢測。這項公共衛生措施顯著擴大了診斷服務的覆蓋範圍，並加強了對合併感染患者的早期識別，促進了及時的臨床幹預。
- 2023年4月，德國羅伯特‧科赫研究所發布了新的流行病學數據，強調各醫療中心的丁型肝炎病毒檢測數量正逐漸增加。這些發現，加上政府資助的肝炎病例數位追蹤系統，正在改善即時監測，並增強國家醫療系統應對丁型肝炎病毒負擔的反應能力。
- 2023年2月，法國國家健康與醫學研究院（INSERM）啟動了一項多中心臨床研究，旨在評估新型丁型肝炎（HDV）聯合療法的長期有效性。這項研究涉及法國、德國和西班牙的學術醫院，代表下一代HDV治療證據生成方面邁出了重要一步，鞏固了歐洲在肝病研究領域的領導地位。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 EUROPE CLINICAL TRIAL MARKET FOR EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
4.4 DISTRIBUTION OF PRODUCTS BY PHASE
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF HEPATITIS
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS
6.4.2 SLOW REGULATORY APPROVALS
7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 ACUTE HEPATITIS D
7.3 CHRONIC HEPATITIS D
8 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY (LIVER TRANSPLANT)
8.3 MEDICATION
8.3.1 APPROVED THERAPIES
8.3.1.1 PEGYLATED INTERFERON ALPHA
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)
8.3.2 EMERGING THERAPIES
9 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM
9.1 OVERVIEW
9.2 TABLET
9.3 CAPSULE
9.4 INJECTABLE
10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERIC
11 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 CAPSULE
11.2.3 OTHERS
11.3 PARENTERAL
12 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
13.4 PEDIATRIC
14 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
14.1 OVERVIEW
14.2 CONTAMINATED NEEDLES
14.3 EXPOSURE TO INFECTED BLOOD
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION
14.5 OTHERS
15 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CENTERS
15.4 HOME CARE SETTING
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
16.4 OTHERS
17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 NETHERLANDS
17.1.7 SWITZERLAND
17.1.8 RUSSIA
17.1.9 BELGIUM
17.1.10 TURKEY
17.1.11 DENMARK
17.1.12 SWEDEN
17.1.13 POLAND
17.1.14 NORWAY
17.1.15 FINLAND
17.1.16 REST OF EUROPE
18 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 GILEAD SCIENCES, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PIPELINE PRODUCT
20.1.5 RECENT DEVELOPMENTS
20.2 GENENTECH, INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 ALNYLAM PHARMACEUTICALS, INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PIPELINE PRODUCT
20.3.4 RECENT DEVELOPMENTS
20.4 ASSEMBLY BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PIPELINE PRODUCT
20.4.4 RECENT DEVELOPMENTS
20.5 EIGER BIOPHARMACEUTICALS
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 PIPELINE PRODUCT
20.5.6 RECENT DEVELOPMENT
20.6 GLOBEIMMUNE INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PRODUCT
20.6.3 RECENT DEVELOPMENT
20.7 HUAHUI HEALTH LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 PIPELINE PRODUCT
20.7.3 RECENT DEVELOPMENT
20.8 JOHNSON & JOHNSON SERVICES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PIPELINE PRODUCT
20.8.4 RECENT DEVELOPMENT
20.9 PHARMAESSENTIA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PIPELINE PRODUCT
20.9.4 RECENT DEVELOPMENT
20.1 REPLICOR
20.10.1 COMPANY SNAPSHOT
20.10.2 PIPELINE PRODUCT
20.10.3 RECENT DEVELOPMENTS
20.11 VIR BIOTECHNOLOGY, INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALAYSIS
20.11.3 PRODUCT PIPELINE
20.11.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 EMERGING NOVEL THERAPIES FOR HDV
TABLE 2 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 EUROPE ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 EUROPE CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 EUROPE SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 11 EUROPE TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 EUROPE CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 EUROPE INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 EUROPE BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 EUROPE GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 EUROPE PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 EUROPE FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 EUROPE MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 25 EUROPE ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 EUROPE GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 EUROPE PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 29 EUROPE CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 EUROPE EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 EUROPE BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 EUROPE HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 EUROPE SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 EUROPE HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 EUROPE RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 EUROPE AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 41 EUROPE DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 49 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 53 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 57 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 63 GERMANY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 GERMANY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 67 GERMANY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 69 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 70 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 72 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 73 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 74 GERMANY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 77 FRANCE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 FRANCE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 FRANCE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 83 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 84 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 85 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 86 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 87 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 88 FRANCE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 91 U.K. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 U.K. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 U.K. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 97 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 98 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 99 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 100 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 102 U.K. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 105 ITALY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 ITALY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 108 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 109 ITALY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 111 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 112 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 113 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 114 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 115 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 ITALY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 119 SPAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 SPAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 123 SPAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 125 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 126 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 127 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 128 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 130 SPAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 131 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 133 NETHERLANDS MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 NETHERLANDS APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 136 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 137 NETHERLANDS ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 139 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 140 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 141 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 142 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 143 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 144 NETHERLANDS RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 147 SWITZERLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 SWITZERLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 151 SWITZERLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 153 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 154 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 155 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 156 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 157 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 SWITZERLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 161 RUSSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 RUSSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 165 RUSSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 167 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 168 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 169 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 170 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 171 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 172 RUSSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 175 BELGIUM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 BELGIUM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 179 BELGIUM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 181 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 182 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 183 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 184 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 185 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 186 BELGIUM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 189 TURKEY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 TURKEY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 193 TURKEY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 195 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 196 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 197 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 198 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 199 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 200 TURKEY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 203 DENMARK MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 204 DENMARK APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 207 DENMARK ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 208 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 209 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 210 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 211 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 212 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 213 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 214 DENMARK RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 217 SWEDEN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 218 SWEDEN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 221 SWEDEN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 223 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 224 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 225 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 226 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 227 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 SWEDEN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 231 POLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 POLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 234 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 235 POLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 237 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 238 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 239 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 240 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 241 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 242 POLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 245 NORWAY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 NORWAY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 249 NORWAY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 251 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 252 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 253 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 254 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 255 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 256 NORWAY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 258 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 259 FINLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 FINLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 263 FINLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 265 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 266 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 267 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 268 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 270 FINLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 2 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 15 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023
FIGURE 16 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 18 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023
FIGURE 20 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 21 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 22 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 23 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023
FIGURE 24 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 25 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 26 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023
FIGURE 28 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 29 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 30 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 31 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 32 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 33 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 34 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023
FIGURE 36 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 37 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023
FIGURE 40 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 41 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 42 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023
FIGURE 44 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)
FIGURE 45 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)
FIGURE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023
FIGURE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 49 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 53 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 54 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)
FIGURE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
